CANNABIDIOL

Information current as at: 1 July 2026

PBAC meeting date: November 2026
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Epidyolex®
Form and strength:
  • Oral liquid 100 mg per mL, 100 mL
Submission sponsor:
JAZZ PHARMACEUTICALS ANZ PTY LTD
Condition/indication:
(therapeutic use)
  • Dravet syndrome (DS) Lennox-Gastaut syndrome (LGS)
Listing requested:
To request an increase in the maximum quantity per prescription of Epidyolex from one bottle to five bottles when used in the treatment of seizures associated with DS and LGS.
Funding program:
PBS General Schedule
Request authority level:
Authority Required (STREAMLINED)
PBAC Submission type:
Change to existing listing (–)
Comment:
--
Other PBAC consideration:
--

Progress Details

Submission received for:
November 2026 PBAC meeting
2Opportunity for consumer comment:
Open 22/07/2026 and close 16/09/2026 (see PBS Website)
3PBAC meeting:
Has not yet occurred
4PBAC outcome published:
Pending PBAC outcome (see PBAC Outcomes)
5Lodgement of required documentation:
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Case ID
a1270
Page last updated
23 July 2026
Return to the Medicine Status Listing
v.9.19